Free Ghana: October 2016

Tuesday, October 18, 2016

Synalar

Synalar is a brand name of fluocinolone topical, approved by the FDA in the following formulation(s):

SYNALAR (fluocinolone acetonide - cream; topical)

Manufacturer: MEDIMETRIKS PHARMS

Approved Prior to Jan 1, 1982

Strength(s): 0.01% ^[RLD]^[AT], 0.025% ^[RLD]^[AT], 0.025% ^[RLD]^[AT]

SYNALAR (fluocinolone acetonide - ointment; topical)

Manufacturer: MEDIMETRIKS PHARMS

Approved Prior to Jan 1, 1982

Strength(s): 0.025% ^[RLD]^[AT]

SYNALAR (fluocinolone acetonide - solution; topical)

Manufacturer: MEDIMETRIKS PHARMS

Approved Prior to Jan 1, 1982

Strength(s): 0.01% ^[RLD]^[AT]

Has a generic version of Synalar been approved?

Yes. The following products are equivalent to Synalar:

fluocinolone acetonide cream; topical

Manufacturer: FOUGERA

Approval date: December 16, 1982

Strength(s): 0.01% ^[AT], 0.025% ^[AT]

Manufacturer: G AND W LABS

Approval date: July 26, 1988

Strength(s): 0.01% ^[AT], 0.025% ^[AT]

Manufacturer: TARO

Approval date: April 27, 1982

Strength(s): 0.025% ^[AT]

fluocinolone acetonide ointment; topical

Manufacturer: FOUGERA

Approval date: December 16, 1982

Strength(s): 0.025% ^[AT]

Manufacturer: G AND W LABS

Approval date: July 26, 1988

Strength(s): 0.025% ^[AT]

Manufacturer: TARO

Approval date: September 15, 1994

Strength(s): 0.025% ^[AT]

fluocinolone acetonide solution; topical

Manufacturer: FOUGERA

Approval date: December 16, 1982

Strength(s): 0.01% ^[AT]

Manufacturer: TARO

Approval date: September 11, 1985

Strength(s): 0.01% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Synalar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Synalar.

Has a generic version of Isordil been approved?

Yes. The following products are equivalent to Isordil:

isosorbide dinitrate tablet; oral

Manufacturer: PAR PHARM

Approval date: March 12, 1987

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: PAR PHARM

Approval date: October 2, 1987

Strength(s): 20MG ^[AB]

Manufacturer: PAR PHARM

Approval date: January 12, 1988

Strength(s): 30MG ^[AB]

Manufacturer: SANDOZ

Approval date: January 7, 1988

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: SANDOZ

Approval date: April 7, 1988

Strength(s): 20MG ^[AB]

Manufacturer: WATSON LABS

Approval date: January 6, 1988

Strength(s): 5MG ^[AB]

Manufacturer: WATSON LABS

Approval date: January 7, 1988

Strength(s): 10MG ^[AB]

Manufacturer: WEST WARD

Approval date: October 29, 1987

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: WEST WARD

Approval date: November 2, 1987

Strength(s): 20MG ^[AB]

Manufacturer: WEST WARD

Approval date: January 10, 2007

Strength(s): 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isordil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Isordil.

Has a generic version of Topamax been approved?

A generic version of Topamax has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Topamax and have been approved by the FDA:

topiramate capsule; oral

Manufacturer: MYLAN

Approval date: October 14, 2009

Strength(s): 15MG ^[AB], 25MG ^[AB]

Manufacturer: SANDOZ

Approval date: October 14, 2009

Strength(s): 15MG ^[AB], 25MG ^[AB]

Manufacturer: TEVA

Approval date: April 17, 2009

Strength(s): 15MG ^[AB], 25MG ^[AB]

Manufacturer: WATSON LABS

Approval date: April 15, 2009

Strength(s): 15MG ^[AB], 25MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: October 14, 2009

Strength(s): 15MG ^[AB], 25MG ^[AB]

topiramate tablet; oral

Manufacturer: ACCORD HLTHCARE

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: APOTEX INC

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: AUROBINDO PHARMA

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: CIPLA LTD

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: INVAGEN PHARMS

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: MYLAN

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: RANBAXY

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB]

Manufacturer: SUN PHARM INDS LTD

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: TEVA

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: TORRENT PHARMS

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: UNICHEM

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: UPSHER SMITH

Approval date: January 7, 2010

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: WATSON LABS

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: WOCKHARDT USA

Approval date: September 1, 2010

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: March 27, 2009

Strength(s): 100MG ^[AB], 200MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topamax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Treatment of migraine
Patent 5,998,380
Issued: December 7, 1999
Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
Assignee(s): New England Medical Center Hospitals, Inc.
A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula: ##STR1##
Patent expiration dates:
- October 13, 2015
  ✓
  Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE
- April 13, 2016
  ✓
  Pediatric exclusivity

Migraine treatment method using topiramate and related compounds
Patent 6,503,884
Issued: January 7, 2003
Inventor(s): Bruce L.; Ehrenberg & Anita K.; Wagner
Assignee(s): New England Medical Center Hospitals, Inc.
A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
Patent expiration dates:
- October 13, 2015
  ✓
  Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE
- April 13, 2016
  ✓
  Pediatric exclusivity

Treatment of migraine
Patent 7,018,983
Issued: March 28, 2006
Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
Assignee(s): New England Medical Center Hospitals, Inc.
A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
Patent expiration dates:
- October 13, 2015
  ✓
  Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE
- April 13, 2016
  ✓
  Pediatric exclusivity

Pharmaceutical composition of topiramate
Patent 7,125,560
Issued: October 24, 2006
Inventor(s): Thakur; Madhav S. & Kotwal; Pramod M. & Gibbs; Irwin S.
Assignee(s): Ortho-McNeil Pharmaceutical, Inc.
The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.
Patent expiration dates:
- March 1, 2019
  ✓
  Patent use: TREATMENT OF SEIZURES
- September 1, 2019
  ✓
  Pediatric exclusivity

Treatment of migraine
Patent 7,498,311
Issued: March 3, 2009
Inventor(s): Ehrenberg; Bruce L. & Wagner; Anita K.
Assignee(s): New England Medical Center Hospitals, Inc.
A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula:
Patent expiration dates:
- October 13, 2015
  ✓
  Patent use: PROPHYLACTIC TREATMENT OF MIGRAINE
- April 13, 2016
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- December 22, 2012 - INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
- June 22, 2013 - PEDIATRIC EXCLUSIVITY

Has a generic version of Treximet been approved?

No. There is currently no therapeutically equivalent version of Treximet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Treximet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
Patent 6,060,499
Issued: May 9, 2000
Inventor(s): Plachetka; John R.
Assignee(s): Pozen, Inc.
This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
Patent expiration dates:
- August 14, 2017
  ✓
  Patent use: TREATMENT OF MIGRAINE
  ✓
  Drug product

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Patent 6,586,458
Issued: July 1, 2003
Inventor(s): John R.; Plachetka
Assignee(s): Pozen Inc.
The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
Patent expiration dates:
- August 14, 2017
  ✓
  Patent use: TREATMENT OF MIGRAINE
  ✓
  Drug product

Multilayer dosage forms containing NSAIDs and triptans
Patent 7,332,183
Issued: February 19, 2008
Inventor(s): Plachetka; John R. & Kothapalli; Venkata Markandeya & Gilbert; Donna L.
Assignee(s): Pozen Inc.
The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.
Patent expiration dates:
- October 2, 2025
  ✓
  Patent use: TREATMENT OF MIGRAINE
  ✓
  Drug product

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
Patent 8,022,095
Issued: September 20, 2011
Inventor(s): Plachetka; John R.
Assignee(s): Pozen, Inc.
The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.
Patent expiration dates:
- August 14, 2017
  ✓
  Patent use: TREATMENT OF MIGRAINE
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- April 15, 2011 - NEW COMBINATION

Has a generic version of Topicort LP been approved?

No. There is currently no therapeutically equivalent version of Topicort LP available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topicort LP. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Topicort LP.

Has a generic version of Triglide been approved?

No. There is currently no therapeutically equivalent version of Triglide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Triglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Spray drying process and compositions of fenofibrate
Patent 6,696,084
Issued: February 24, 2004
Inventor(s): Gary W.; Pace & Awadesh K.; Mishra & Robert A.; Snow & Indu; Parikh & Pol-Henri W.; Guivarc'h
Assignee(s): RTP Pharma Inc.
The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
Patent expiration dates:
- September 11, 2021
  ✓
  Patent use: A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
  ✓
  Drug substance
  ✓
  Drug product

Has a generic version of Trizivir been approved?

No. There is currently no therapeutically equivalent version of Trizivir available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trizivir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Therapeutic nucleosides
Patent 5,034,394
Issued: July 23, 1991
Inventor(s): Daluge; Susan M.
Assignee(s): Burroughs Wellcome Co.
The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
Patent expiration dates:
- December 18, 2011
  ✓
  Drug substance
  ✓
  Drug product
- June 18, 2012
  ✓
  Pediatric exclusivity

Crystalline oxathiolane derivatives
Patent 5,905,082
Issued: May 18, 1999
Inventor(s): Roberts; Tony Gordon & Evans; Paul
Assignee(s): Glaxo Group Limited
(-)cis-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(IH)-pyrimidine-2-on e in crystalline form, in particular as needle-shaped or bypyramidyl crystals, pharmaceutical formulations thereof, methods for their preparation and their use in medicine.
Patent expiration dates:
- May 18, 2016
  ✓
  Patent use: TREATMENT OF HIV
  ✓
  Drug substance
  ✓
  Drug product
- November 18, 2016
  ✓
  Pediatric exclusivity

Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Patent 6,294,540
Issued: September 25, 2001
Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
Assignee(s): Glaxo Wellcome Inc.
The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
Patent expiration dates:
- May 14, 2018
  ✓
  Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
  ✓
  Drug substance
  ✓
  Drug product
- November 14, 2018
  ✓
  Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
  ✓
  Pediatric exclusivity

Synergistic combinations of zidovudine, 1592U89 and 3TC
Patent 6,417,191
Issued: July 9, 2002
Inventor(s): David Walter; Barry & Martha Heider; St. Clair
Assignee(s): GlaxoSmithKline
The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol (1592U89), 3′-azido-3′-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
Patent expiration dates:
- March 28, 2016
  ✓
  Patent use: TREATMENT OF HIV
  ✓
  Drug product

Has a generic version of Tenex been approved?

Yes. The following products are equivalent to Tenex:

guanfacine hydrochloride tablet; oral

Manufacturer: AMNEAL PHARM

Approval date: November 25, 1998

Strength(s): EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB]

Manufacturer: EPIC PHARMA

Approval date: February 28, 1997

Strength(s): EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: January 27, 1997

Strength(s): EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: October 17, 1995

Strength(s): EQ 1MG BASE ^[AB], EQ 2MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tenex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Tenex.

Has a generic version of Norditropin Nordiflex been approved?

No. There is currently no therapeutically equivalent version of Norditropin Nordiflex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norditropin Nordiflex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical formulation
Patent 5,849,700
Issued: December 15, 1998
Inventor(s): S.o slashed.rensen; Hans Holmegaard & Skriver; Lars & Hoelgaard; Annie Rassing
Assignee(s): Novo Nordisk A/S
A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
Patent expiration dates:
- December 15, 2015
  ✓
  Patent use: THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN

Pharmaceutical formulation
Patent 5,849,704
Issued: December 15, 1998
Inventor(s): S.o slashed.rensen; Hans Holmegaard & Skriver; Lars & Hoelgaard; Annie Rassing
Assignee(s): Novo Nordisk A/S
A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
Patent expiration dates:
- December 15, 2015
  ✓
  Patent use: THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- September 20, 2010 - TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
- October 31, 2011 - TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
- May 31, 2014 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Maxalt been approved?

No. There is currently no therapeutically equivalent version of Maxalt available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Maxalt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Triazole containing indole derivatives
Patent 5,298,520
Issued: March 29, 1994
Inventor(s): Baker; Raymond & Matassa; Victor G. & Street; Leslie J.
Assignee(s): Merck Sharp & Dohme Limited
A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
Patent expiration dates:
- June 29, 2012
  ✓
  Patent use: TREATMENT OF ACUTE MIGRAINE ATTACKS
  ✓
  Drug substance
  ✓
  Drug product
- December 29, 2012
  ✓
  Pediatric exclusivity

Imidazole, triazole and tetrazole derivatives
Patent 5,602,162
Issued: February 11, 1997
Inventor(s): Baker; Raymond & Matassa; Victor G. & Street; Leslie J.
Assignee(s): Merck, Sharp & Dohme Ltd.
A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
Patent expiration dates:
- February 11, 2014
  ✓
  Sponsor has requested patent be delisted
- August 11, 2014
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- December 15, 2014 - NEW PATIENT POPULATION
- June 15, 2015 - PEDIATRIC EXCLUSIVITY

Has a generic version of Benicar HCT been approved?

No. There is currently no therapeutically equivalent version of Benicar HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benicar HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
Patent 5,616,599
Issued: April 1, 1997
Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
Assignee(s): Sankyo Company, Limited
Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
Patent expiration dates:
- April 25, 2016
  ✓
  Patent use: USE AS AN ANTIHYPERTENSIVE AGENT
  ✓
  Drug substance
  ✓
  Drug product
- October 25, 2016
  ✓
  Pediatric exclusivity

Pharmaceutical composition
Patent 6,878,703
Issued: April 12, 2005
Inventor(s): Sada; Toshio & Mizuno; Makoto
Assignee(s): Sankyo Company, Limited
A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics: The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
Patent expiration dates:
- November 19, 2021
  ✓
  Patent use: TREATMENT OF HYPERTENSION
  ✓
  Sponsor has requested patent be delisted
- May 19, 2022
  ✓
  Pediatric exclusivity

Has a generic version of Betimol been approved?

No. There is currently no therapeutically equivalent version of Betimol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Betimol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Betimol.

Has a generic version of Bactrim DS been approved?

Yes. The following products are equivalent to Bactrim DS:

SEPTRA DS (sulfamethoxazole; trimethoprim tablet; oral)

Manufacturer: MONARCH PHARMS

Approved Prior to Jan 1, 1982

Strength(s): 800MG;160MG ^[AB]

SULFAMETHOPRIM-DS (sulfamethoxazole; trimethoprim tablet; oral)

Manufacturer: NOVEL LABS INC

Approval date: February 15, 1985

Strength(s): 800MG;160MG ^[AB]

SULFAMETHOXAZOLE AND TRIMETHOPRIM (sulfamethoxazole; trimethoprim tablet; oral)

Manufacturer: AMNEAL PHARMS NY

Approval date: January 27, 2005

Strength(s): 800MG;160MG ^[AB]

Manufacturer: AUROBINDO PHARMA

Approval date: February 16, 2010

Strength(s): 800MG;160MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: December 22, 2010

Strength(s): 800MG;160MG ^[AB]

Manufacturer: VINTAGE

Approval date: January 25, 2007

Strength(s): 800MG;160MG ^[AB]

Manufacturer: VISTA PHARMS

Approval date: October 7, 2005

Strength(s): 800MG;160MG ^[AB]

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (sulfamethoxazole; trimethoprim tablet; oral)

Manufacturer: SANDOZ

Approval date: May 19, 1982

Strength(s): 800MG;160MG ^[AB]

Manufacturer: TEVA

Approval date: June 2, 1987

Strength(s): 800MG;160MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bactrim DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Bactrim DS.

Has a generic version of Evoxac been approved?

A generic version of Evoxac has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Evoxac and have been approved by the FDA:

CEVIMELINE (cevimeline hydrochloride capsule; oral)

Manufacturer: APOTEX INC

Approval date: August 25, 2011

Strength(s): 30MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evoxac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Composition and method for treating Sjoegren syndrome disease
Patent 5,340,821
Issued: August 23, 1994
Inventor(s): Abe; Nobuaki & Takeshita; Yasuyoshi
Assignee(s): Snow Brand Milk Products Co., Ltd.
A composition for treating a Sjoegren syndrome disease is disclosed. The composition comprising derivative of spirooxathiolane-quinuclidine of the following formula (I), ##STR1## wherein Z is .dbd.CR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, alkyl, cyclopentyl, cyclohexyl, aryl, diarylmethylol, or alkyl which may be substituted by one or more aryl groups, or an acid addition salt thereof, or an acid addition salt thereof, as an effective component. Especially effective is an administration of a hydrochloric acid addition salt of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine.
Patent expiration dates:
- July 7, 2013
  ✓
  Patent use: TREATING SJOEGREN SYNDROME

Has a generic version of Ponstel been approved?

Yes. The following products are equivalent to Ponstel:

mefenamic acid capsule; oral

Manufacturer: LUPIN LTD

Approval date: July 22, 2011

Strength(s): 250MG ^[AB]

Manufacturer: MICRO LABS LTD

Approval date: November 19, 2010

Strength(s): 250MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ponstel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ponstel.

Has a generic version of Plan B One-Step been approved?

No. There is currently no therapeutically equivalent version of Plan B One-Step available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plan B One-Step. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plan B One-Step.

Related Exclusivities

Exclusivity expiration dates:
- July 10, 2012 - NEW PRODUCT

Has a generic version of Plaquenil been approved?

Yes. The following products are equivalent to Plaquenil:

hydroxychloroquine sulfate tablet; oral

Manufacturer: IPCA LABS LTD

Approval date: June 14, 2007

Strength(s): 200MG ^[AB]

Manufacturer: MYLAN

Approval date: May 29, 1998

Strength(s): 200MG ^[AB]

Manufacturer: SANDOZ

Approval date: November 30, 1995

Strength(s): 200MG ^[AB]

Manufacturer: SANDOZ

Approval date: January 27, 1996

Strength(s): 200MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: September 30, 1994

Strength(s): 200MG ^[AB]

Manufacturer: WATSON LABS

Approval date: November 30, 1995

Strength(s): 200MG ^[AB]

Manufacturer: WEST WARD

Approval date: August 15, 2007

Strength(s): 200MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: September 21, 2007

Strength(s): 200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plaquenil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plaquenil.

Has a generic version of Imitrex been approved?

Yes. The following products are equivalent to Imitrex:

sumatriptan succinate injectable; subcutaneous

Manufacturer: APP PHARMS

Approval date: March 2, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: APP PHARMS

Approval date: September 18, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: BEDFORD

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: BEDFORD LABS

Approval date: August 11, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: JHP PHARMS

Approval date: July 9, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: PAR PHARM

Approval date: October 9, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: June 10, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: July 28, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SANDOZ

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: WOCKHARDT

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

sumatriptan succinate tablet; oral

Manufacturer: AUROBINDO PHARMA

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: DR REDDYS LABS INC

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: November 2, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: ORCHID HLTHCARE

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: RANBAXY

Approval date: February 9, 2009

Strength(s): EQ 100MG BASE ^[AB]

Manufacturer: RANBAXY

Approval date: August 10, 2009

Strength(s): EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: TEVA

Approval date: February 9, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imitrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Imitrex.

Has a generic version of Paremyd been approved?

No. There is currently no therapeutically equivalent version of Paremyd available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paremyd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Paremyd.

Has a generic version of Zofran ODT been approved?

A generic version of Zofran ODT has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zofran ODT and have been approved by the FDA:

ondansetron tablet, orally disintegrating; oral

Manufacturer: AUROBINDO PHARMA

Approval date: April 12, 2010

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: BARR

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: June 27, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: MYLAN

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: NESHER PHARMS

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: PAR PHARM

Approval date: December 26, 2006

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: RANBAXY

Approval date: February 24, 2011

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: SANDOZ

Approval date: August 13, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: August 2, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: TEVA

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zofran ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Freeze-dried compositions
Patent 5,955,488
Issued: September 21, 1999
Inventor(s): Winterborn; Ian Keith
Assignee(s): Glaxo Wellcome Inc.
The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
Patent expiration dates:
- November 14, 2015
- May 14, 2016
  ✓
  Pediatric exclusivity

Ondansetron freeze-dried dosage form compositions for oral administration
Patent 6,063,802
Issued: May 16, 2000
Inventor(s): Winterborn; Ian Keith
Assignee(s): Glaxco Wellcome Inc.
The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
Patent expiration dates:
- November 14, 2015
- May 14, 2016
  ✓
  Pediatric exclusivity

Has a generic version of Androderm been approved?

No. There is currently no therapeutically equivalent version of Androderm available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Androderm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Androderm.

Related Exclusivities

Exclusivity expiration dates:
- October 20, 2014 - NEW STRENGTH

Tuesday, October 18, 2016

SYNALAR (fluocinolone acetonide - cream; topical)

SYNALAR (fluocinolone acetonide - ointment; topical)

SYNALAR (fluocinolone acetonide - solution; topical)

Has a generic version of Synalar been approved?

fluocinolone acetonide cream; topical

fluocinolone acetonide ointment; topical

fluocinolone acetonide solution; topical

Related Patents

See also...

ISORDIL (isosorbide dinitrate - tablet; oral)

Has a generic version of Isordil been approved?

isosorbide dinitrate tablet; oral

Related Patents

See also...

TOPAMAX (topiramate - capsule; oral)

TOPAMAX (topiramate - tablet; oral)

Has a generic version of Topamax been approved?

topiramate capsule; oral

topiramate tablet; oral

Related Patents

Related Exclusivities

See also...

TREXIMET (naproxen sodium; sumatriptan succinate - tablet; oral)

Has a generic version of Treximet been approved?

Related Patents

Related Exclusivities

See also...

TOPICORT LP (desoximetasone - cream; topical)

Has a generic version of Topicort LP been approved?

Related Patents

See also...

TRIGLIDE (fenofibrate - tablet; oral)

Has a generic version of Triglide been approved?

Related Patents

See also...

TRIZIVIR (abacavir sulfate; lamivudine; zidovudine - tablet; oral)

Has a generic version of Trizivir been approved?

Related Patents

See also...

TENEX (guanfacine hydrochloride - tablet; oral)

Has a generic version of Tenex been approved?

guanfacine hydrochloride tablet; oral

Related Patents

See also...

NORDITROPIN NORDIFLEX (somatropin recombinant - injectable; injection)

Has a generic version of Norditropin Nordiflex been approved?

Related Patents

Related Exclusivities

See also...

MAXALT (rizatriptan benzoate - tablet; oral)

Has a generic version of Maxalt been approved?

Related Patents

Related Exclusivities

See also...

BENICAR HCT (hydrochlorothiazide; olmesartan medoxomil - tablet; oral)

Has a generic version of Benicar HCT been approved?

Related Patents

See also...

BETIMOL (timolol - solution/drops; ophthalmic)

Has a generic version of Betimol been approved?

Related Patents

See also...

BACTRIM DS (sulfamethoxazole; trimethoprim - tablet; oral)

Has a generic version of Bactrim DS been approved?

SEPTRA DS (sulfamethoxazole; trimethoprim tablet; oral)

SULFAMETHOPRIM-DS (sulfamethoxazole; trimethoprim tablet; oral)

SULFAMETHOXAZOLE AND TRIMETHOPRIM (sulfamethoxazole; trimethoprim tablet; oral)

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (sulfamethoxazole; trimethoprim tablet; oral)

Related Patents

See also...

EVOXAC (cevimeline hydrochloride - capsule; oral)

Has a generic version of Evoxac been approved?

CEVIMELINE (cevimeline hydrochloride capsule; oral)

Related Patents

See also...

PONSTEL (mefenamic acid - capsule; oral)

Has a generic version of Ponstel been approved?

mefenamic acid capsule; oral

Related Patents